Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Mustea

Showing results (111-120 of 172) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancerLukas A Hefler, Nicole Concin, Gerda Hofstetter, et al.
In Vivo (Athens, Greece)|November 4, 2020
Risk Factors for Severe Complications in Ovarian Cancer SurgeryEva Katharina Egger, Natascha Kohls, Matthias B Stope, et al.
Journal for Immunotherapy of Cancer|September 29, 2025
Antagonism of estrogen-related receptor-α inhibits mitochondrial oxidative phosphorylation and reduces M2 macrophage infiltration in endometrial cancerJincheng Ma, Xiaodan Mao, Yuan Ren, et al.
Cancers|October 13, 2021
Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 PatientsJalid Sehouli, Alexander Mustea, Guelten Oskay-Özcelik, et al.
Cancer Research|March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancerNelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2007
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II studyDominique Koensgen, Dirk Stengel, Antje Belau, et al.
Anticancer Research|February 27, 2022
Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial CancerThomas Hecking, Thore Thiesler, Janina Halbe, et al.
Epigenetics|October 22, 2010
Epigenetic quantification of tumor-infiltrating T-lymphocytesJalid Sehouli, Christoph Loddenkemper, Tatjana Cornu, et al.
Cancer Research Communications|February 26, 2024
Immune Profiling of Vulvar Squamous Cell Cancer Discovers a Macrophage-rich Subtype Associated with Poor PrognosisMateja Condic, Andrea Rohr, Soheila Riemann, et al.
Gynecologic and Obstetric Investigation|July 25, 2017
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer NetworkDominique Koensgen, Matthias B Stope, Ivana Tuerbachova, et al.
Pageof 18

Showing results (111-120 of 172) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancerLukas A Hefler, Nicole Concin, Gerda Hofstetter, et al.
In Vivo (Athens, Greece)|November 4, 2020
Risk Factors for Severe Complications in Ovarian Cancer SurgeryEva Katharina Egger, Natascha Kohls, Matthias B Stope, et al.
Journal for Immunotherapy of Cancer|September 29, 2025
Antagonism of estrogen-related receptor-α inhibits mitochondrial oxidative phosphorylation and reduces M2 macrophage infiltration in endometrial cancerJincheng Ma, Xiaodan Mao, Yuan Ren, et al.
Cancers|October 13, 2021
Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 PatientsJalid Sehouli, Alexander Mustea, Guelten Oskay-Özcelik, et al.
Cancer Research|March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancerNelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2007
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II studyDominique Koensgen, Dirk Stengel, Antje Belau, et al.
Anticancer Research|February 27, 2022
Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial CancerThomas Hecking, Thore Thiesler, Janina Halbe, et al.
Epigenetics|October 22, 2010
Epigenetic quantification of tumor-infiltrating T-lymphocytesJalid Sehouli, Christoph Loddenkemper, Tatjana Cornu, et al.
Cancer Research Communications|February 26, 2024
Immune Profiling of Vulvar Squamous Cell Cancer Discovers a Macrophage-rich Subtype Associated with Poor PrognosisMateja Condic, Andrea Rohr, Soheila Riemann, et al.
Gynecologic and Obstetric Investigation|July 25, 2017
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer NetworkDominique Koensgen, Matthias B Stope, Ivana Tuerbachova, et al.
Pageof 18